Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRL-1 Intranasal Diazepam in Japanese Pediatric Patients With or at Risk for Status Epilepticus
jRCT2031220265Phase 3Completed
- Sponsor
- Aculys Pharma, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of diazepam in status epilepticus (SE) and epilepsy (3 arms), sponsored by Aculys Pharma, Inc. Primary endpoint: Seizure cessation without recurrence after single NRL-1 dose (Part 1). Started Dec 2022; status: completed.
02
Drugs
diazepam
03
Conditions
status epilepticus (SE)epilepsy
Beyond the preview
Go deeper on jRCT2031220265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220265.